INFORM2 - NIVENT (IC 2018-07)

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies

Ouvert à Paris depuis le : 08/02/2021
Public cible : Child
Phase : Phase I/II

Description de l'essai

The aim of this trial is to determine preliminary activity of the combination treatment with nivolumab and entinostat in children and adolescents with high risk refractory/relapsed/progressive tumors harboring a high mutational load, high PD-L1 mRNA expression or focal MYC(N) amplification and explore activity in biomarker low tumors (low mutational load, low PD-L1 mRNA expression and non-MYC(N) amplified).

Url of the trial

Investigateur principal

GUDRUN SCHLEIERMACHER

Médecin

Contacter